Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study-Reference-Cited by-同舟云学术

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Published:2024-09 Issue: Volume: Page:
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Choueiri Toni K,Albiges Laurence,Barthélémy Philippe,Iacovelli Roberto,Emambux Sheik,Molina-Cerrillo Javier,Garmezy Benjamin,Barata Pedro,Basu Arnab,Bourlon Maria T,Moon Helen,Ratta Raffaele,McKay Rana R,Chehrazi-Raffle Alexander,Hammers Hans,Heng Daniel Y C,Braendle Edgar,Beckermann Kathryn E,McGregor Bradley A,Motzer Robert J

Publisher

Elsevier BV

Reference19 articles.

1. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial;Pal;Lancet,2023

2. Systemic therapy for metastatic renal-cell carcinoma;Choueiri;N Engl J Med,2017

3. Summary from the first Kidney Cancer Research Summit, September 12–13, 2019: a focus on translational research;Choueiri;J Natl Cancer Inst,2021

4. Beyond conventional immune-checkpoint inhibition—novel immunotherapies for renal cell carcinoma;Braun;Nat Rev Clin Oncol,2021

5. Novel therapeutic approaches and the evolution of drug development in advanced kidney cancer;Ravi;Cancer J,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma;The Lancet;2024-09